Alpha-1 Antitrypsin Deficiency

📋 Key Information Summary

📋

Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant disorder caused by mutations in the SERPINA1 gene on chromosome 14, leading to deficiency of the serine protease inhibitor alpha-1 antitrypsin (AAT).
Over 150 allelic variants exist; clinically significant phenotypes include PiMM (normal), PiMZ (mild heterozygous risk), PiSZ (moderate risk), and PiZZ (severe deficiency, classical disease).
PiZZ homozygotes have serum AAT levels <11 µmol/L (approximately <50 mg/dL) and carry the highest risk for both pulmonary emphysema and chronic liver disease.
Serum AAT is an acute-phase reactant — always measure CRP simultaneously; normal AAT during inflammation may mask true deficiency.
Confirmatory diagnosis requires phenotyping by isoelectric focusing (IEF) or genotyping by SERPINA1 gene analysis, both available through Australian reference laboratories.
Liver disease in AATD is confined to severe deficiency phenotypes (PiZZ, rare PiNull variants); heterozygous states (PiMZ, PiSZ) do not typically cause clinically significant liver injury.
Hepatic manifestations include neonatal cholestasis (10–20% of PiZZ neonates), paediatric cirrhosis, adult chronic hepatitis progressing to cirrhosis, and hepatocellular carcinoma (HCC) risk.
Liver biopsy shows characteristic PAS-positive, diastase-resistant (PAS-D) globules within hepatocytes — these represent polymerised, misfolded AAT retained in the endoplasmic reticulum.
Management centres on surveillance for cirrhosis and HCC (ultrasound every 6 months, AFP), supportive measures, and referral for liver transplantation in decompensated cirrhosis or HCC meeting criteria.
Liver transplantation cures both the hepatic disease and restores normal serum AAT levels (the liver is the sole site of AAT synthesis).
Augmentation therapy (IV AAT protein replacement) treats emphysema only — it has no role in managing liver disease.
Abstinence from smoking and alcohol is essential; smoking accelerates pulmonary decline; alcohol compounds hepatotoxicity in a liver already burdened by protein misfolding.
Family genetic counselling should be offered to all first-degree relatives of confirmed AATD patients; cascade screening identifies at-risk individuals early.

Genetics & Diagnosis

SERPINA1 Gene

Alpha-1 antitrypsin (AAT) is a 52-kDa glycoprotein encoded by the SERPINA1 gene located on chromosome 14q32.13. The gene spans approximately 12.2 kb and comprises five exons. AAT is synthesised primarily by hepatocytes and, to a lesser extent, by intestinal epithelial cells and monocytes. Its principal physiological function is inhibition of neutrophil elastase, protecting lung parenchyma from proteolytic destruction. However, the liver disease of AATD arises not from a functional deficit of circulating AAT, but from the consequences of misfolded protein accumulation within the hepatocyte endoplasmic reticulum (ER).

The Z mutation (Glu342Lys) causes a conformational change that favours polymerisation of AAT molecules within the ER, resulting in both intracellular protein aggregation (hepatotoxic) and reduced serum levels (pneumotoxic). The S mutation (Glu264Val) also causes some intracellular retention, but to a far lesser degree, and is more prevalent in Iberian and Australasian populations.

⚠️

Key pathogenic mechanism: Liver injury in AATD is a gain-of-toxic-function (protein polymerisation within hepatocytes), not a loss of protective function in the lung. This is why augmentation therapy — which restores circulating AAT — does not address hepatic pathology.

Clinically Significant Phenotypes

Phenotype	Serum AAT Level	Liver Risk	Lung Risk	Estimated Prevalence
PiMM	20–53 µmol/L (normal)	Nil	Nil (background risk)	~95% of European-descent populations
PiMZ	12–28 µmol/L (~50–60% of normal)	Very low; rarely clinically significant	Mild increase, especially with smoking	~3–5%
PiSZ	8–16 µmol/L (~40% of normal)	Low–moderate	Moderate increase	~0.5–1%
PiZZ	<11 µmol/L (<50 mg/dL)	Significant — primary hepatic risk	High — classical emphysema	~1 in 2000–5000 (European-descent)
PiNull/Null	Undetectable	No liver disease (no protein produced to polymerise)	Severe emphysema	Rare

Diagnostic Approach

AATD remains significantly underdiagnosed in Australia. Indications for testing include unexplained liver disease at any age, early-onset emphysema (age <45 years), emphysema in non-smokers, necrotising panniculitis, unexplained bronchiectasis, and family history of AATD.

Step 1 — Serum AAT Level

Quantitative serum AAT is measured by nephelometry or immunoturbidimetry. The reference range is 20–53 µmol/L (1.0–2.7 g/L in some laboratories).

🚨

Critical interpretive pitfall: AAT is an acute-phase reactant. During intercurrent infection, inflammation, pregnancy, or malignancy, serum AAT may rise into the normal range even in PiZZ homozygotes. Always request a concurrent CRP. If CRP is elevated and AAT is "normal," repeat testing when inflammation has resolved or proceed directly to phenotyping/genotyping.

Step 2 — Confirmatory Phenotyping or Genotyping

Serum AAT level alone cannot define the specific allele combination. Confirmatory testing is essential:

Isoelectric focusing (IEF) — The traditional phenotyping method. Separates AAT isoforms by charge to identify M, S, Z, and rarer variants. Available through reference laboratories including SA Pathology, Royal Prince Alfred Hospital (Sydney), and PathWest (Perth). MBS item coverage applies to the requesting clinician's laboratory referral.
Genotyping by SERPINA1 gene analysis — PCR-based detection of the S and Z alleles (the two most common deficiency variants). Does not detect rare or null alleles. Commercial kits (e.g., Progenika Biopharma) are available. Full gene sequencing is available for atypical cases through specialist genetic services (e.g., Victorian Clinical Genetics Services, Genetic Health Queensland).
Next-generation sequencing (NGS) panels — Increasingly used in tertiary centres; can detect all SERPINA1 variants including null mutations.

In Australia, testing is accessible through public hospital pathology for clinically indicated cases. Medicare rebates apply under general biochemistry/genetic testing MBS items when clinically justified.

Investigations Summary

Available

Serum AAT level (quantitative)

Nephelometry/immunoturbidimetry. Request concurrently with CRP. Available in all Australian hospital and major private laboratories. MBS-rebatable under general biochemistry.

Available

CRP (concomitant)

Essential to interpret AAT levels accurately. Widely available.

Referral

AAT phenotyping by isoelectric focusing

Reference laboratories: SA Pathology, RPAH (Sydney), PathWest (Perth). Turnaround 2–4 weeks.

Referral

SERPINA1 genotyping (S and Z alleles)

PCR-based; commercial kits. Does not detect null alleles. Available through specialist genetics services.

Specialist

Full SERPINA1 gene sequencing

For atypical phenotypes or null allele detection. VCGS (Melbourne), Genetic Health Queensland. Requires geneticist referral.

Available

Liver function tests, liver ultrasound

Baseline and surveillance. HCC screening per Australasian Society for Viral Hepatitis (ASVH) / RACGP guidelines.

Liver Manifestations

Liver disease in AATD is a direct consequence of the gain-of-toxic-function mechanism: the Z-mutant AAT protein polymerises within the endoplasmic reticulum of hepatocytes, triggering ER stress, autophagy overload, mitochondrial dysfunction, and ultimately hepatocyte injury and apoptosis. Importantly, only severe deficiency phenotypes — primarily PiZZ and, rarely, PiNull — develop clinically significant liver disease. Heterozygous carriers (PiMZ, PiSZ) may show mild histological changes on biopsy but almost never develop progressive hepatic fibrosis.

⚠️

Clinical pearl: PiNull homozygotes produce no AAT protein at all and therefore develop severe lung disease but no liver disease — there is no misfolded protein to accumulate in hepatocytes. This underscores the pathogenic mechanism and guides prognostic counselling.

Neonatal Cholestasis

Approximately 10–20% of PiZZ neonates present with conjugated hyperbilirubinaemia (neonatal hepatitis syndrome) within the first weeks of life. Features include prolonged jaundice, acholic stools, hepatomegaly, and elevated conjugated bilirubin, GGT, and transaminases. The differential diagnosis is broad and includes biliary atresia, Alagille syndrome, galactosaemia, and neonatal haemochromatosis.

Investigation should follow standard neonatal cholestasis pathways: liver function, GGT, biliary ultrasound, hepatobiliary scintigraphy (HIDA), and consideration of liver biopsy if biliary atresia cannot be excluded.
If AATD is diagnosed, hepatobiliary scintigraphy and, if necessary, intraoperative cholangiography may still be required to exclude biliary atresia — a treatable surgical emergency that must not be missed.
Most PiZZ neonatal cholestasis resolves spontaneously by 6–12 months, but affected infants require long-term follow-up as they are at higher risk for progressive fibrosis and cirrhosis in childhood.

Paediatric Cirrhosis

A subset of PiZZ children (estimated 2–3% overall, higher among those with prior neonatal cholestasis) develop progressive hepatic fibrosis and cirrhosis during childhood. Presentation may be with:

Hepatomegaly detected incidentally
Elevated transaminases on screening
Splenomegaly and features of portal hypertension (varices, ascites)
Growth failure or nutritional deficiency

Paediatric gastroenterology and hepatology referral is essential. Management includes nutritional optimisation, fat-soluble vitamin supplementation (A, D, E, K), monitoring for portal hypertension complications, and assessment for liver transplantation if decompensation occurs.

Adult Chronic Hepatitis and Cirrhosis

Adult PiZZ patients may develop chronic liver disease with a variable and often insidious course. Some present with established cirrhosis in the absence of prior recognised childhood liver disease. Features include:

Elevated transaminases (often mild, ALT/AST 1.5–3× ULN)
Hepatomegaly
Progressive fibrosis on serial assessment (transient elastography or biopsy)
Decompensation: ascites, variceal bleeding, hepatic encephalopathy, coagulopathy

It is critical to exclude concurrent liver pathology: viral hepatitis (B and C), metabolic-associated steatotic liver disease (MASLD), autoimmune hepatitis, haemochromatosis, and Wilson disease should be assessed. Co-pathologies significantly accelerate fibrosis.

Hepatocellular Carcinoma (HCC) Risk

🚨

HCC screening is mandatory in all PiZZ patients with established cirrhosis. HCC can also arise in AATD livers without preceding cirrhosis, though this is less common. Surveillance should continue indefinitely in cirrhotic patients.

The accumulation of polymerised AAT in hepatocytes creates a pro-oncogenic microenvironment through chronic ER stress, unfolded protein response (UPR) activation, NF-κB signalling, and oxidative stress. HCC in AATD occurs predominantly in cirrhotic livers, but cases in non-cirrhotic PiZZ livers have been reported, raising important surveillance implications.

Histopathology — Liver Biopsy

Liver biopsy, while not always required for diagnosis (particularly in the setting of confirmed PiZZ genotype with characteristic clinical features), remains the gold standard for staging fibrosis and excluding alternative diagnoses. The hallmark finding is:

PAS-positive, diastase-resistant (PAS-D) globules — Round, eosinophilic, 1–40 µm intracytoplasmic inclusions within periportal (Zone 1) hepatocytes. These represent accumulated polymerised Z-AAT protein. They are best demonstrated by PAS staining followed by diastase digestion: glycogen is removed, leaving the proteinaceous AAT globules visible.
Additional histological features may include portal and periportal inflammation, interface hepatitis, bile duct proliferation, hepatocyte necrosis, and variable fibrosis progressing from periportal to bridging to cirrhosis.
Immunohistochemistry using anti-AAT antibodies confirms that PAS-D globules contain AAT and can distinguish AATD from other causes of PAS-positive inclusions (e.g., alpha-fibrinogenogenemia).

ℹ️

Non-invasive fibrosis assessment: Transient elastography (FibroScan®) is widely available in Australian hepatology centres and can be used to monitor fibrosis progression serially, reducing the need for repeated liver biopsies. However, biopsy remains important when the diagnosis is uncertain or alternative liver diseases need exclusion.

Management

Surveillance for Cirrhosis and HCC

All PiZZ patients — even those with currently normal liver function — should be enrolled in a structured surveillance programme given the life-long risk of progressive liver disease and HCC.

Surveillance Component	Frequency	Details
Liver function tests (ALT, AST, ALP, GGT, bilirubin, albumin, INR)	Every 6–12 months	Detect biochemical progression; albumin and INR assess synthetic function
Full blood count	Every 12 months	Thrombocytopenia as early marker of portal hypertension/splenomegaly
Liver ultrasound ± AFP	Every 6 months (if cirrhosis confirmed)	HCC screening per Cancer Council Australia / RACGP guidelines for chronic liver disease
Transient elastography (FibroScan®)	Every 12–24 months	Non-invasive fibrosis staging; track progression over time
Upper GI endoscopy	At diagnosis of cirrhosis, then per variceal screening protocol	Assess for oesophageal and gastric varices; band ligation if indicated
Nutritional assessment	Every 12 months	Fat-soluble vitamin levels (A, D, E, K) especially if cholestasis present

Supportive and Preventive Measures

Smoking cessation — Absolute priority. Smoking accelerates pulmonary decline and is independently hepatotoxic. Provide pharmacotherapy (varenicline [Champix® — note current PBS supply limitations], nicotine replacement therapy [NRT], bupropion [Zyban®]) and behavioural support. NRT and varenicline are PBS-listed.
Alcohol abstinence — Strongly recommended. Alcohol compounds the hepatotoxic effects of misfolded AAT accumulation and accelerates fibrosis. There is no safe threshold. Counselling, referral to Drug and Alcohol services, and consideration of naltrexone or acamprosate if alcohol dependence coexists.
Hepatitis A and B vaccination — All AATD patients should be immunised against hepatitis A and B if non-immune. Standard schedule: Hep A (Havrix® 1440 — 2 doses 6–12 months apart), Hep B (Engerix-B® — 0, 1, 6 months). Both are PBS-listed for at-risk populations including chronic liver disease.
Avoid hepatotoxic medications where possible; use paracetamol at standard doses (≤4 g/day in adults with normal liver function; ≤2 g/day if cirrhosis). Avoid methotrexate and isoniazid unless essential with specialist oversight.
Obesity and metabolic syndrome management — MASLD co-pathology accelerates fibrosis. Maintain healthy BMI through diet and exercise.

Augmentation Therapy — Lung Disease Only

🚨

Augmentation therapy does NOT treat liver disease. IV AAT protein replacement restores circulating AAT levels to protect the lung from neutrophil elastase-mediated destruction. It has no effect on the intrahepatic accumulation of misfolded Z-AAT protein. Augmentation therapy is indicated for pulmonary disease in PiZZ patients with FEV₁ 35–65% predicted and confirmed emphysema.

In Australia, augmentation therapy (Prolastin® or Respreeza® — pooled human plasma-derived AAT, 60 mg/kg IV weekly) is available through specialist respiratory services. It is not PBS-listed for this indication and typically requires hospital-based administration and authority/institutional funding. It is only effective for lung disease and should not be prescribed for hepatic manifestations.

Liver Transplantation

Liver transplantation remains the definitive treatment for decompensated cirrhosis or HCC meeting transplant criteria in AATD. Key points:

Transplantation cures the liver disease and, importantly, restores normal serum AAT levels because the donor liver produces normal (PiMM) AAT.
Lung disease does not improve after liver transplantation — pulmonary damage from prior protease–antiprotease imbalance is irreversible.
Australian liver transplant centres: Royal Prince Alfred Hospital (Sydney), Austin Hospital (Melbourne), Princess Alexandra Hospital (Brisbane), Sir Charles Gairdner Hospital (Perth), Flinders Medical Centre (Adelaide).
Listing criteria follow standard Australian organ allocation guidelines (Transplantation Society of Australia and New Zealand — TSANZ). HCC within Milan criteria (single tumour ≤5 cm, or up to 3 nodules each ≤3 cm, no macrovascular invasion) qualifies for standard listing.
Combined liver–lung transplantation may be considered for PiZZ patients with both end-stage liver and lung disease, though outcomes and availability are limited in Australia.

Emerging Therapies

Several novel approaches targeting the hepatic pathogenesis of AATD are in clinical trials:

Gene therapy — AAV-mediated gene addition and mRNA-based approaches aim to restore normal AAT expression. Phase I/II trials are ongoing internationally.
Small-molecule correctors — Drugs (e.g., alvelestat, camostat) designed to prevent Z-AAT polymerisation within the ER, potentially addressing both lung and liver disease simultaneously.
siRNA / antisense oligonucleotides — Hepatocyte-targeted gene silencing to reduce production of the mutant Z-AAT protein, thereby decreasing intracellular accumulation.

Patients should be informed about clinical trial opportunities through the Australian AATD Registry and relevant hepatology or respiratory research networks.

Family Genetic Counselling

Cascade screening of first-degree relatives is strongly recommended once AATD is confirmed in an index case:

Offer serum AAT level and confirmatory phenotyping/genotyping to parents, siblings, and children of confirmed PiZZ individuals.
Genetic counselling should explain autosomal co-dominant inheritance, penetrance variability, and the implications of heterozygous (PiMZ) versus homozygous (PiZZ) status.
Reproductive counselling for PiZZ individuals: partner testing is recommended; if partner is also a carrier, each pregnancy carries a 25% chance of PiZZ offspring.
Resources: Australian Genetic Alliance, Genetic Support Network of Victoria, Centre for Genetics Education (NSW).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Prevalence and burden

The prevalence of AATD alleles in Aboriginal and Torres Strait Islander populations has not been well characterised, but chronic liver disease is disproportionately prevalent and is a leading cause of morbidity and mortality. AATD may be an underrecognised contributor. AIHW data consistently show that liver disease contributes significantly to the burden of disease in ATSI communities, with cirrhosis mortality rates 3–5 times those of non-Indigenous Australians.

Diagnostic barriers

Access to serum AAT testing, phenotyping, and genotyping is limited in remote and very remote communities. Specialist hepatology and genetics services are concentrated in metropolitan centres, creating significant geographic barriers. Delayed diagnosis leads to presentation with advanced liver disease. Telehealth hepatology consultations through the Australian Telehealth Network can bridge some gaps.

Co-morbidity burden

Hepatitis B prevalence is significantly higher in ATSI populations (chronic HBV prevalence ~3–6% in some communities versus ~0.9% nationally). Co-existing HBV or hepatitis C with AATD dramatically accelerates fibrosis progression. HBV vaccination coverage in ATSI adolescents and young adults requires continued effort. MASLD, alcohol-related liver disease, and haemochromatosis (HFE mutations) may also coexist.

Smoking and alcohol

Tobacco smoking prevalence remains substantially higher in ATSI communities (~40% versus ~11% nationally). Given that smoking is the dominant modifier of pulmonary outcomes in AATD and independently hepatotoxic, culturally safe smoking cessation programmes are essential. Alcohol-related harm also contributes to liver disease burden; AOD services must be accessible and culturally appropriate.

Surveillance and follow-up

Engagement with regular liver surveillance (ultrasound, LFTs, elastography) requires strong primary care partnerships. Aboriginal Community Controlled Health Organisations (ACHCHOs) play a vital role in chronic disease management. Integration of AATD liver surveillance into existing chronic disease registers (e.g., CATSINaM, PATS frameworks) should be considered. Patient-held health records and recall systems improve follow-up rates.

Family screening

Cascade screening for AATD in first-degree relatives may be facilitated through ACHCHOs and community health workers, leveraging family-centred care models that are culturally appropriate and effective in ATSI communities. Genetic counselling services should be offered through culturally safe pathways, with attention to kinship structures and community decision-making processes.

📚 References

1. Strnad P, McElvaney NG, Lomas DA. Alpha₁-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443–1455. doi:10.1056/NEJMra1910234
2. Greve J, DeLuca D, Hebestreit H, et al. Alpha-1 antitrypsin deficiency — an overview of the clinical features, diagnosis, and management. Eur Respir J. 2023;61(4):2201697. doi:10.1183/13993003.01697-2022
3. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.
4. Teckman JH, Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep. 2014;16(1):367. doi:10.1007/s11894-013-0367-8
5. Tanash HA, Nystedt-Duzakin M, Montero LC, et al. Cause of death in severe alpha-1-antitrypsin deficiency — a nationwide registry-based study. Respir Res. 2021;22(1):86. doi:10.1186/s12931-021-01662-7
6. Australian Institute of Health and Welfare (AIHW). Chronic liver disease and cirrhosis deaths in Australia. Canberra: AIHW; 2023. Available from: https://www.aihw.gov.au
7. Cancer Council Australia. Clinical practice guidelines for the prevention, early detection and management of hepatocellular carcinoma. Sydney: Cancer Council Australia; 2020. Available from: https://wiki.cancer.org.au/australiawiki/index.php?oldid=197654
8. Greve J, McElvaney NG, Ferrarotti I, et al. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013;8:149. doi:10.1186/1750-1172-8-149
9. Transplantation Society of Australia and New Zealand (TSANZ). Organ transplantation from deceased donors: policies and guidelines. TSANZ; 2023. Available from: https://www.tsanz.com.au
10. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 10th ed. East Melbourne: RACGP; 2024.
11. Maurer SF, Kjaergaard M, Tanash HA, et al. Alpha-1 antitrypsin deficiency and liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(9):843–854.
12. Australasian Society for Viral Hepatitis (ASVH). Australian national hepatitis B and C strategies: clinical guidelines. ASVH; 2023.